Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...

For pregnant women who received the bivalent prefusion F subunit-based respiratory syncytial virus (RSV) vaccine (RSVpreF; ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Loqtorzi (toripalimab) showed significant improvement in progression-free survival for acral melanoma compared to standard chemotherapy in a phase 3 trial. Acral melanoma, a rare and aggressive ...

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...

For years, we've thought of autism as lying on a spectrum, but emerging evidence suggests that it comes in several distinct ...

Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...

“Our findings indicate that the vaccine provided a significant enhanced level of protection against these infections in the ...

A systematic review and meta-analysis of 15 studies found that ketogenic diets were associated with short-term reductions in ...